{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:22Z","timestamp":1793806162319,"version":"4.6.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["R03DK141708"],"award-info":[{"award-number":["R03DK141708"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"American Kidney Fund","award":["Clinical Scientist in Nephrology Award"],"award-info":[{"award-number":["Clinical Scientist in Nephrology Award"]}],"id":[{"id":"https:\/\/ror.org\/04hjvcm52","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,11]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n eGFR discordance was associated with higher risk of AKI in allogeneic hematopoietic stem cell transplantation and adoptive T-cell therapies.<\/jats:p>\n <\/jats:list-item>\n \n Among hematopoietic stem cell transplantation recipients, eGFR discordance was associated with slower time-to-platelet engraftment.<\/jats:p>\n <\/jats:list-item>\n \n Among adoptive T-cell recipients, eGFR discordance was associated with prolonged cytopenia.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Discordance between eGFR on the basis of serum creatinine (eGFR\n cr<\/jats:sub>\n ) versus cystatin C (eGFR\n cys<\/jats:sub>\n ) is associated with adverse outcomes in patients with and without cancer. We hypothesized that eGFR discordance is associated with AKI and death after hematopoietic stem cell transplantation (HSCT) or receipt of adoptive T-cell therapies.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a multicenter study of adults receiving allogeneic HSCT and adoptive T-cell therapies who had paired serum creatinine and cystatin C values obtained in the 30 days preceding conditioning or lymphodepleting chemotherapy. The primary exposure was eGFR discordance, defined as eGFR\n cys<\/jats:sub>\n \u226530% lower than eGFR\n cr<\/jats:sub>\n . The primary outcome was a composite outcome of AKI (\u226550% increase in serum creatinine or receipt of KRT) or death within 90 days after HSCT or adoptive T-cell infusion. Secondary outcomes included time-to-platelet engraftment in HSCT and prolonged cytopenia in adoptive T-cell recipients. We used multivariable logistic regression and cause-specific Cox regression with inverse probability weighting to adjust for confounders.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 274 patients receiving HSCT (median age, 65 years; interquartile range, 52\u201371; 43% female), 86 (31%) had an eGFR discordance. Among 236 adoptive T-cell recipients (median age, 67 years; interquartile range, 60\u201374; 59% female), 78 (33%) had a discordance in eGFR. eGFR discordance was associated with higher odds of AKI or death in HSCT (odds ratio, 1.75; 95% confidence interval, 1.03 to 3.02) and adoptive T-cell recipients (odds ratio, 2.37; 95% confidence interval, 1.12 to 4.94). However, adjustment for eGFR\n cr-cys<\/jats:sub>\n attenuated these associations in both cohorts. eGFR discordance was also associated with slower time-to-platelet engraftment in HSCT recipients and prolonged cytopenia after adoptive T-cell therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n A pretreatment eGFR discordance was associated with AKI or death in HSCT and adoptive T-cell recipients; however, this association was attenuated after adjusting for eGFR\n cr-cys<\/jats:sub>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000001119","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:06:02Z","timestamp":1776787562000},"page":"2470-2482","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1707-9988","authenticated-orcid":false,"given":"Api","family":"Chewcharat","sequence":"first","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5326-0365","authenticated-orcid":false,"given":"Rajesh","family":"Anumolu","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"},{"name":"UMass Chan Medical School, Worcester, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2471-5921","authenticated-orcid":false,"given":"Aditya","family":"Suresh","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-6654","authenticated-orcid":false,"given":"Karla Sofia","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2713-5471","authenticated-orcid":false,"given":"Jessica L.","family":"Ortega","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-6820","authenticated-orcid":false,"given":"Ansh K.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana M.","family":"Zargari","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia B.","family":"Rubman","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firasat M.","family":"Alikhan","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-6299","authenticated-orcid":false,"given":"Raad B.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Adult Survivorship Program, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5810-1192","authenticated-orcid":false,"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-090X","authenticated-orcid":false,"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-4736","authenticated-orcid":false,"given":"Rizwan","family":"Romee","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-8322","authenticated-orcid":false,"given":"Roman M.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Adult Survivorship Program, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"4","key":"B1-20261104","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/jcsm.12969","article-title":"Muscle mass and estimates of renal function: a longitudinal cohort study","volume":"13","author":"Groothof","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"4","key":"B2-20261104","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/jcsm.13006","article-title":"Creatinine-cystatin C ratio and mortality in cancer patients: a retrospective cohort study","volume":"13","author":"Jung","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"5","key":"B3-20261104","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: core curriculum 2021","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B4-20261104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B5-20261104","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.ajkd.2020.05.017","article-title":"The difference between cystatin C- and creatinine-based estimated GFR and associations with frailty and adverse outcomes: a cohort analysis of the systolic blood pressure intervention trial (SPRINT)","volume":"76","author":"Potok","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B6-20261104","doi-asserted-by":"crossref","first-page":"e2148940","DOI":"10.1001\/jamanetworkopen.2021.48940","article-title":"Association of intraindividual difference in estimated glomerular filtration rate by creatinine vs cystatin C and end-stage kidney disease and mortality","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"9","key":"B7-20261104","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2215\/CJN.0000000000000217","article-title":"Discrepancies between cystatin C-based and creatinine-based eGFR","volume":"18","author":"Farrington","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B8-20261104","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.ajkd.2023.04.002","article-title":"Discordances between creatinine- and cystatin C; based estimated GFR and adverse clinical outcomes in routine clinical practice","volume":"82","author":"Carrero","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B9-20261104","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","article-title":"Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors","volume":"79","author":"Chute","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B10-20261104","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1093\/oncolo\/oyad001","article-title":"Safety of immune checkpoint inhibitors in patients with advanced chronic kidney disease: a retrospective cohort study","volume":"28","author":"Tiu","year":"2023","journal-title":"Oncologist."},{"issue":"8","key":"B11-20261104","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"issue":"6","key":"B12-20261104","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ekir.2025.04.003","article-title":"The discrepancy between estimated GFR cystatin C and estimated GFR creatinine at 3 months after hospitalization and long-term adverse outcomes","volume":"10","author":"Wen","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"19","key":"B13-20261104","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"New Engl J Med."},{"issue":"9981","key":"B14-20261104","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/S0140-6736(15)60266-5","article-title":"Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial","volume":"385","author":"Wilson","year":"2015","journal-title":"Lancet."},{"issue":"5","key":"B15-20261104","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/CIRCHEARTFAILURE.109.926030","article-title":"A global rank end point for clinical trials in acute heart failure","volume":"3","author":"Felker","year":"2010","journal-title":"Circ Heart Fail."},{"issue":"4","key":"B16-20261104","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"issue":"4","key":"B18-20261104","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"21","key":"B21-20261104","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.2025.17578","article-title":"Discordance in creatinine- and cystatin C\u2013based eGFR and clinical outcomes: a meta-analysis","volume":"334","author":"Estrella","year":"2025","journal-title":"JAMA."},{"issue":"3","key":"B22-20261104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/cancers18030351","article-title":"GFR evaluation among patients with cancer: insights and clinical implications","volume":"18","author":"Arora","year":"2026","journal-title":"Cancers (Basel)."},{"issue":"6","key":"B23-20261104","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/j.ajkd.2025.06.018","article-title":"A drug-wide association study on medications associated with cystatin c;estimated GFR","volume":"86","author":"Inker","year":"2025","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"B24-20261104","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/jcsm.13469","article-title":"Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer","volume":"15","author":"Hanna","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"4","key":"B25-20261104","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"B26-20261104","doi-asserted-by":"crossref","first-page":"317","DOI":"10.34067\/KID.0000000692","article-title":"Kidney disease and hematopoietic stem cell transplantation","volume":"6","author":"Renaghan","year":"2025","journal-title":"Kidney360."},{"key":"B27-20261104","doi-asserted-by":"crossref","first-page":"110311","DOI":"10.1016\/j.clim.2024.110311","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy: epidemiology, mechanism and prognosis","volume":"266","author":"Yang","year":"2024","journal-title":"Clin Immunol."},{"issue":"2","key":"B28-20261104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"B30-20261104","doi-asserted-by":"crossref","first-page":"102401","DOI":"10.1016\/j.ssresearch.2019.102401","article-title":"Negative ability bias from conditioning on a confounded mediator: a directed interaction test and case study","volume":"87","author":"Zhu","year":"2020","journal-title":"Soc Sci Res."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:02:15Z","timestamp":1793804535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000001119","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2025-11-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}